Scarica l'app Stockscreener
14.03
0.91%
-0.255
Precedente Chiudi:
$14.28
Aprire:
$14.05
Volume 24 ore:
30,581
Relative Volume:
0.10
Capitalizzazione di mercato:
$74.21M
Reddito:
$858.00K
Utile/perdita netta:
$-8.98M
Rapporto P/E:
-68.12
EPS:
-0.2059
Flusso di cassa netto:
$-29.81M
1 W Prestazione:
+59.35%
1M Prestazione:
+74.26%
6M Prestazione:
+176.89%
1 anno Prestazione:
+495.14%
Intervallo 1D:
$13.86
$14.18
Intervallo di 1 settimana:
$8.70
$15.31
Portata 52W:
$2.16
$15.31
Rallybio Corp Stock (RLYB) Company Profile
Nome
Rallybio Corp
Settore
Industria
Telefono
203- 859-3820
Indirizzo
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
14.03 | 75.54M | 858.00K | -8.98M | -29.81M | -0.2059 |
VRTX
Vertex Pharmaceuticals Inc
|
426.56 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
706.91 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.62 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.12 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
304.81 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-07 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-17 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-10 | Iniziato | Wedbush | Outperform |
| 2022-12-09 | Iniziato | JP Morgan | Overweight |
| 2022-02-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-08-23 | Iniziato | Cowen | Outperform |
| 2021-08-23 | Iniziato | Evercore ISI | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
Mostra tutto
Rallybio Corp Borsa (RLYB) Ultime notizie
[RW] Rallybio Corp SEC Filing - Stock Titan
Rallybio stock surges after receiving $50M termination fee By Investing.com - Investing.com Nigeria
Rallybio stock surges after receiving $50M termination fee - Investing.com
Rallybio merger scrapped; New Haven biotech to receive $50M breakup fee - Hartford Business Journal
Rallybio Corporation Files Form 8-K with SEC Detailing Waiver Agreement and Entity Information - Minichart
RLYB Stock Under Pressure As Merger Scrutiny Mounts - timothysykes.com
Rallybio Receives Termination Fee After Candid Deal Collapse - TipRanks
Rallybio, Candid and UCB Sign Waiver; $50 Million Fee Follows Merger Termination - TradingView
Rallybio CorpCandid terminates merger agreement with Rallybio on May 3, 2026SEC filing - marketscreener.com
Rallybio (RLYB) to receive $50,000,000 after Candid chooses UCB deal - Stock Titan
RLYB - Finviz
RLYB Stock Chart | RALLYBIO CORP (NASDAQ:RLYB) - ChartMill
[S-4/A] Rallybio Corp Amended Business Combination Registration | RLYB SEC FilingForm S-4/A - Stock Titan
Rallybio Corporation (RLYB) Sector Rotation | Rallybio Corporation notches 13.9% EPS beat on narrower lossCommunity Buy Signals - Xã Vĩnh Công
Is Rallybio Corporation (RLYB) stock a good opportunity (Institutional Demand) 2026-04-20Social Flow Trades - Cổng thông tin điện tử Tỉnh Sơn La
Johnson & Johnson Reduces Stake in Rallybio Corp: A Strategic Po - GuruFocus
Rallybio Corporation (RLYB) Stock: Price Structure (Hovering) 2026-04-16Trending Stock Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? - Eastern Progress
J&J (NYSE: JNJ) discloses 152,901‑share stake in Rallybio (RLYB) - Stock Titan
Will Rallybio Corporation (RLYB) Stock Outperform S&P 500 | Price at $8.24, Down 2.31%Top Breakouts - UBND thành phố Hải Phòng
RLYB Stock Quote - richtv.io
Rallybio Investors Confront Significant Dilution in Merger as $47.5M Valuation Marks Major Downturn from Earlier Projections - Bitget
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasda - ChartMill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
Setup Watch: Can Rallybio Corporation sustain earnings growth2026 Movers & Precise Entry and Exit Recommendations - baoquankhu1.vn
Is Rallybio Corporation (RLYB) Stock cyclical or stable | Price at $8.43, Up 0.36%Short Term Trading - Xã Thanh Hà
RLYB Technical Analysis & Stock Price Forecast - Intellectia AI
Rallybio CMO Departs Amid Pending Candid Therapeutics Merger - The Globe and Mail
AI Stocks: Is Rallybio Corporation stock trending bullishWeekly Trade Report & Daily Price Action Insights - baoquankhu1.vn
Rallybio chief medical officer departs as company announces leadership change By Investing.com - Investing.com South Africa
Rallybio chief medical officer departs as company announces leadership change - Investing.com Australia
Rallybio (RLYB) CMO Steven Ryder exits as Candid Therapeutics merger proceeds - Stock Titan
RLYB Should I Buy - Intellectia AI
RALLYBIO CORP (NASDAQ:RLYB) Passes Minervini Trend and High Growth Momentum Filters - ChartMill
Rallybio (NASDAQ:RLYB) Rating Increased to Hold at Wall Street Zen - Defense World
Rallybio to acquire Candid Therapeutics - MSN
Rallybio to acquire Candid Therapeutics in $505M merger deal - MSN
If You Invested $1,000 in Rallybio Corp (RLYB) - Stock Titan
Here's Why We're Watching Rallybio's (NASDAQ:RLYB) Cash Burn Situation - 富途牛牛
Halper Sadeh LLC is Investigating Whether RLYB, TALK, UNF are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Tiny biotech Rallybio stock surges as $500 million-backed merger fuels investor optimism - msn.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations - marketscreener.com
Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization - TipRanks
Halper Sadeh LLC is Investigating Whether TALK, JTAI, RLYB are Obtaining Fair Deals for their Shareholders - The Norfolk Daily News
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB - GlobeNewswire Inc.
Rallybio Corporation 2025 10-K: Clinical-Stage Rare Disease Biotech, Pipeline, Partnerships, and Regulatory Overview - Minichart
RLYB Surges on Revenue and Merger Hype Why the Stock Still Dropped - Bitget
Stock Recap: What hedge funds are buying Rallybio CorporationPortfolio Value Summary & Weekly High Conviction Ideas - baoquankhu1.vn
Rallybio (NASDAQ: RLYB) to become Candid after merger, $505.5M financing - Stock Titan
Rallybio 2025 10-K: $0.858M Revenue, $(8.98)M Net Loss - TradingView
Rallybio Corp Azioni (RLYB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):